This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"Discover the groundbreaking success of the first-in-human implantation of the BiVACOR Total ArtificialHeart by the Texas Heart Institute, offering hope for he
A research team co-led by a physician-scientist at the University of Arizona College of MedicineTucson's Sarver Heart Center found that a subset of artificialheart patients can regenerate heart muscle, which may open the door to new ways to treat and perhaps someday cure heart failure.
Surgeons at Cincinnati-based The Christ Hospital performed a successful human implantation of the BiVACOR Total ArtificialHeart, marking the fourth hospital in the U.S. to complete the procedure as part of the FDA's early feasibility study.
Physician-scientists found that a subset of artificialheart patients can regenerate heart muscle, which may open the door to new ways to treat and perhaps someday cure heart failure.
ArtificialHeart Valves Who needs artificialheart valves? The 4 heart valves work continuously to keep blood flowing to the lungs and to the body. Sometimes, disease may damage the heart valves so that they function poorly or stop working completely. When damaged valves can no longer [.]
hospital to perform a BiVACOR Total ArtificialHeart implantation as part of the FDA's early feasibility study. Banner-University Medical Center Phoenix has become the third U.S.
Some heart failure patients with artificialhearts have been able to regenerate heart muscle, potentially paving the way for future heart failure treatment options, according to a study published Nov. 21 in Circulation.
A prototype of an expanding artificialheart valve could make a big dent in the number of surgeries that many kids born with congenital heart disease need.
Cardiovascular diseases, particularly coronary heart disease (CHD), have become an epidemic in India. Shockingly, 9 out of every 1000 newborns are diagnosed with CHD annually. This means that 240,000 children born with CHD each year pose a significant challenge for healthcare providers and families.
29, 2025 Scandinavian Real Heart AB (recently aannouncedthat its total artificialheart, Realheart TAH, has been granted Humanitarian Use Device (HUD) designation by the U.S. RealheartTAH is a total artificialheart that mimics the structure and physiological function of the human heart.
Background Valvular heart disease is a major health concern worldwide. Bibliometric analysis of studies on managing patients with artificialheart valves has not been previously performed. The effective management of patients undergoing valve replacement determines their prognosis.
“Patients with this severe condition also have increased mortality and may experience more frequent heart failure hospitalizations,” said Dr. O’Neill. The condition is often caused by an enlarged heart or the patient’s native damaged valve flaps.
UA) independently predicted the combined endpoint (left ventricular assist device, total artificialheart implantation, heart transplantation or all-cause mortality) (hazard ratio (HR): 1.10 (1.03–1.17), p=0.004) as well as all-cause mortality (HR: 1.15 (1.06–1.25), p=0.001).
The Annals of Thoracic Surgery September 2016 Marshall Jacobs The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2016 Update on Research The Annals of Thoracic Surgery September 2016 Lawrence Schwartz The Perioperative Use of Dexmedetomidine in Pediatric Patients with Congenital Heart Disease: An Analysis from the Congenital Cardiac (..)
The Annals of Thoracic Surgery September 2016 Marshall Jacobs The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2016 Update on Research The Annals of Thoracic Surgery September 2016 Lawrence Schwartz The Perioperative Use of Dexmedetomidine in Pediatric Patients with Congenital Heart Disease: An Analysis from the Congenital Cardiac (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content